Sialyllactose preserves residual hearing after cochlear implantation

Area of Science:

• Oto-neurology
• Pharmacology
• Biomaterials

Background:

• Cochlear implantation aims to restore hearing but can cause residual hearing loss.
• Protecting residual hearing requires atraumatic electrode insertion and pharmacological interventions.
• Osmotic pump-mediated steroid delivery has shown variable outcomes for hearing preservation.

Purpose of the Study:

• To evaluate the efficacy of sialyllactose (SL) in preventing hearing loss and cochlear tissue damage post-implantation.
• To investigate the anti-inflammatory and tissue-protective mechanisms of SL in an animal model.

Main Methods:

• In vitro assessment of SL using HEI-OC1 cells.
• Development of an animal model simulating cochlear implantation electrode insertion damage.
• Delivery of SL via osmotic pumps in the animal model.
• Analysis of hearing threshold shifts, tissue fibrosis, ossification, and inflammatory gene expression.

Main Results:

• Electrode insertion in the animal model led to hearing deterioration, fibrosis, ossification, and increased inflammatory markers.
• SL administration significantly reduced hearing threshold shifts and tissue reactions.
• SL treatment decreased inflammatory markers following electrode insertion.

Conclusions:

• Sialyllactose (SL) demonstrates significant potential as a pharmacological agent for hearing preservation during cochlear implantation.
• SL effectively mitigates the negative effects of electrode insertion, including inflammation and tissue overgrowth.
• Further research into SL mechanisms could enhance cochlear implant outcomes and understanding of hearing loss.